| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/29/1993 | EP0575844A2 Hydroxamic acid derivatives and pharmaceutical compositions thereof |
| 12/29/1993 | EP0575559A1 TGF-$g(b)1/$g(b)2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA |
| 12/29/1993 | EP0575557A1 Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component |
| 12/29/1993 | EP0575556A1 Palytoxin-related prodrugs and a method for their administration |
| 12/29/1993 | EP0575555A1 Protein-induced morphogenesis |
| 12/29/1993 | EP0575546A1 Prad1 cyclin and its cdna |
| 12/29/1993 | EP0575545A1 Pegylation of polypeptides |
| 12/29/1993 | EP0575537A1 Soluble cd28 proteins and methods of treatment therewith |
| 12/29/1993 | EP0575518A1 Methods and compositions for the selective inhibition of gene expression |
| 12/29/1993 | EP0575500A1 Hiv protease inhibitors |
| 12/29/1993 | EP0575498A1 THE $i(TRK) TYROSINE KINASE RECEPTOR IS THE PHYSIOLOGICAL RECEPTOR FOR NERVE GROWTH FACTOR |
| 12/29/1993 | EP0575490A1 GnRH ANALOGS |
| 12/29/1993 | EP0575485A1 Process for the development of binding mini-proteins |
| 12/29/1993 | EP0575484A1 Method for promoting tissue repair and regeneration |
| 12/29/1993 | EP0575479A1 Production and use of butyrylcholinesterase |
| 12/29/1993 | EP0575464A1 Modified factor vii |
| 12/29/1993 | EP0575452A1 Method for production of a vegetable protein hydrolyzate |
| 12/29/1993 | EP0575432A1 Modified proteins and their use for controlling viral infections |
| 12/29/1993 | EP0575357A1 Human follicle stimulating hormone receptor |
| 12/29/1993 | EP0575339A1 Analogs of acidic fibroblast growth factor having enhanced stability and biological activity |
| 12/29/1993 | EP0575321A1 Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| 12/29/1993 | EP0575311A1 Control of secretion of milk |
| 12/29/1993 | EP0548276A4 Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| 12/29/1993 | EP0539573A4 Genomic modifications with homologous dna targeting |
| 12/29/1993 | EP0538398A4 Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof |
| 12/29/1993 | EP0535038A4 Mammalian adipogenic factors |
| 12/29/1993 | EP0516729B1 N-phenyl n-alkoxycarbonylalkyl glycinamides, preparation method and drugs containing them |
| 12/29/1993 | EP0455682B1 Polypeptides having a human beta-adrenergic receptor activity, and playing a role in lipolytic response, nucleic acids coding for these polypeptides and use of said polypeptides for screening substances which act on these polypeptides |
| 12/29/1993 | EP0454739B1 Method of recovering purified epi protein from a solution especially a fermentation solution |
| 12/29/1993 | EP0396549B1 A drug composition with microspheres and process for its preparation |
| 12/29/1993 | EP0386045B1 Derivatives of type a and type b synergimycins |
| 12/29/1993 | EP0375743B1 Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
| 12/29/1993 | EP0365597B1 Improved processes for the treatment of vascular disease |
| 12/29/1993 | EP0318562B1 Method of selectively inhibiting hiv |
| 12/29/1993 | EP0192671B1 Minactivin |
| 12/29/1993 | CN1079992A Neurotrophic factors having altered receptor binding specificities |
| 12/29/1993 | CN1079971A Polymer-bound taxol derivatives |
| 12/29/1993 | CN1079908A Histamine derivatives and methods for their use as immunomodulators |
| 12/29/1993 | CN1079907A Pharmaceutical composition |
| 12/29/1993 | CN1023295C Method and composition for prophylaxis and treatment of viral infections |
| 12/28/1993 | US5274177 Glutathione-S-lower fatty acid derivative |
| 12/28/1993 | US5274098 Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them |
| 12/28/1993 | US5274087 cDNA coding for carcinoembryonic antigen (CEA) |
| 12/28/1993 | US5274075 Newly identified human epsilon immunoglobulin peptides and related products |
| 12/28/1993 | US5273982 An amidinoaryleneamidoalkylpiperazinyleneacetic acid |
| 12/28/1993 | US5273966 Having two mannose residues attached to the threonine (29) amino acid |
| 12/28/1993 | US5273965 A reduced and hydrolyzed saponin from a Quillaja saponaria extract |
| 12/28/1993 | US5273964 Coating of hydrated collagen product and hydrated collagen-demineralized bone product on tricalcium phosphate ceramic and/or hydroxylapatite ceramic |
| 12/28/1993 | US5273963 Compositions and methods for treating small cell and nonsmall cell lung cancers |
| 12/28/1993 | US5273962 Human urinary thrombomodulin with a modified glycosaminoglycan (GAG) binding site |
| 12/28/1993 | US5273961 Administering IGF-1 before or during but not after renal failure |
| 12/28/1993 | US5273960 High purity crystalline peptides arglysasp and arglysaspval and a process for their preparation |
| 12/28/1993 | US5273901 Genetically engineered coccidiosis sporozoite 21.5 Kb antigen, ac-6b |
| 12/28/1993 | US5273753 A glucosyl- or fructosyltransferase in a solution containing sodium alginate to produce a water-soluble polysaccharide from sucrose |
| 12/28/1993 | US5273743 Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| 12/28/1993 | CA1325695C Peptides with pharmaceutical activity |
| 12/28/1993 | CA1325612C Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions |
| 12/28/1993 | CA1325598C Cosmetic composition |
| 12/28/1993 | CA1325594C Agents for the prophylaxis and therapy of retroviral infections |
| 12/28/1993 | CA1325593C Composition of matter for increasing intracellular atp levels and physical performance levels and for increasing the rate of wound repair |
| 12/28/1993 | CA1325591C Method for treating malignancy and autoimmune disorders in humans |
| 12/27/1993 | CA2096690A1 Hydrophilic creams for delivery of therapeutic agents |
| 12/26/1993 | CA2098166A1 Hydroxamic acid derivatives |
| 12/23/1993 | WO1993025713A1 Compositions and methods for detecting gene rearrangements and translocations |
| 12/23/1993 | WO1993025700A1 Monoclonal antibodies to glycoprotein p |
| 12/23/1993 | WO1993025699A1 Vesicle membrane transport proteins |
| 12/23/1993 | WO1993025698A1 Vector particles resistant to inactivation by human serum |
| 12/23/1993 | WO1993025694A1 Inhibitors of ced-3 and related proteins |
| 12/23/1993 | WO1993025690A1 Recombinant pseudomonas exotoxin with increased activity |
| 12/23/1993 | WO1993025687A1 Crystallization of m-csf |
| 12/23/1993 | WO1993025685A1 Cloning and characterization of the cell death genes ced-3 and ced-4 |
| 12/23/1993 | WO1993025684A1 Therapeutic and diagnostic methods based on neurotrophin-4 expression |
| 12/23/1993 | WO1993025683A1 A gene which prevents programmed cell death |
| 12/23/1993 | WO1993025682A2 Chimeric receptor polypeptides, human h13 proteins and uses thereof |
| 12/23/1993 | WO1993025680A1 ENDOGENOUS LIGANDS FOR CDR4 OF T-CELL RECEPTOR β-CHAINS AND GENES ENCODING THE SAME |
| 12/23/1993 | WO1993025679A1 Novel polypeptides having nmda receptor activity, nucleic acids encoding said polypeptides and applications |
| 12/23/1993 | WO1993025678A1 BETA-SUBUNIT OF A Na+/D-GLUCOSE COTRANSPORTER |
| 12/23/1993 | WO1993025677A1 DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS |
| 12/23/1993 | WO1993025674A1 Non-human animals having retinoblastoma gene alterations |
| 12/23/1993 | WO1993025673A1 In vivo gene therapy with intron-free sequence of interest |
| 12/23/1993 | WO1993025670A1 Purified forms of dnase |
| 12/23/1993 | WO1993025669A1 Dna sequences used in the production of recombinant human bssl/cel in transgenic non-human mammals, and the produced bssl/cel used in infant formulas |
| 12/23/1993 | WO1993025667A1 D-enzyme compositions and methods of their use |
| 12/23/1993 | WO1993025661A1 Heterogeneous proteolipid peptide 139-151-specific t cell clones |
| 12/23/1993 | WO1993025659A1 Glycosaminoglycan specific sulfotransferases |
| 12/23/1993 | WO1993025583A2 Proteinoid carriers and methods for preparation and use thereof |
| 12/23/1993 | WO1993025582A1 A novel endothelial cell molecule mediating lymphocyte binding in man |
| 12/23/1993 | WO1993025581A1 New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| 12/23/1993 | WO1993025580A1 Cyclic peptides that modulate endothelin activity |
| 12/23/1993 | WO1993025579A1 Glucagon-like peptide and insulinotropin derivatives |
| 12/23/1993 | WO1993025577A2 Active component of parathyroid hypertensive factor |
| 12/23/1993 | WO1993025576A2 Peptides having platelet-derived growth factor (pdgf) activity |
| 12/23/1993 | WO1993025575A1 Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus |
| 12/23/1993 | WO1993025574A1 Inhibitors of angiotensin i chymase(s) including human heart chymase |
| 12/23/1993 | WO1993025573A1 Salts of a glutathione alkylester and anaminoacids |
| 12/23/1993 | WO1993025572A1 T-cell monocyte inducing proteins (tmips) |
| 12/23/1993 | WO1993025246A1 Prosthetic devices having enhanced osteogenic properties |
| 12/23/1993 | WO1993025235A1 Aids therapeutics based on hiv-2 vpx peptides |
| 12/23/1993 | WO1993025232A1 The use of hyperimmune milk to increase longevity |
| 12/23/1993 | WO1993025230A1 Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders |